title: The end of the hypoxic EPOch.
authors.affiliation: Division of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University, Stanford, California.
authors.forename: Todd A
authors.initials: TA
authors.lastname: Aguilera
authors.affiliation: Division of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University, Stanford, California. Electronic address: giaccia@stanford.edu.
authors.forename: Amato J
authors.initials: AJ
authors.lastname: Giaccia
mesh_terms: D000740:Anemia / Q000150:complications / Q000628:therapy; D001803:Blood Transfusion; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy*; D015687:Cell Hypoxia / Q000187:drug effects* / Q000502:physiology; D002986:Clinical Trials as Topic; D004921:Erythropoietin / Q000009:adverse effects*; D017341:Etanidazole / Q000627:therapeutic use; D005260:Female; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008920:Misonidazole / Q000627:therapeutic use; D011838:Radiation-Sensitizing Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017467:Receptors, Erythropoietin / Q000378:metabolism; D017211:Treatment Failure; D002583:Uterine Cervical Neoplasms / Q000532:radiotherapy*
chemical_list: D011838:Radiation-Sensitizing Agents; D017467:Receptors, Erythropoietin; D004921:Erythropoietin; D017341:Etanidazole; D008920:Misonidazole